The panel voted six to three that the available evidence doesn't support switching patients to AstraZeneca's camizestrant based on ESR1 mutations detected in circulating tumor DNA.

NEW YORK – Amgen recorded double-digit growth for its KRAS inhibitor Lumakras (sotorasib) in the first quarter of 2025 but also announced it is discontinuing development of AMG 193, an MTA-cooperative ...

The firm posted $19.8 billion in total quarterly revenue, primarily driven by GLP-1 drugs but with contributions from ...

The firm reported an 8 percent increase in sales in the first quarter for its Keytruda family of products, which includes both Keytruda and the subcutaneous Keytruda Qlex.

NEW YORK - The National MPS Society this week said it is awarding a $4 million grant to support a gene therapy program for mucopolysaccharidoses (MPS) IIIB (Sanfilippo syndrome type B) led by ...

Kestrel has dosed the first patient in its Phase I trial evaluating KST-6051 in patients with advanced or metastatic solid tumors with KRAS mutations.

The FDA has also granted bepirovirsen breakthrough therapy designation, building on a fast track designation from the agency in February 2024.